Yoffe Investment Management LLC Invests $462,000 in GSK plc (NYSE:GSK)

Yoffe Investment Management LLC bought a new stake in GSK plc (NYSE:GSK - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 13,657 shares of the pharmaceutical company's stock, valued at approximately $462,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Indiana Trust & Investment Management Co boosted its holdings in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after acquiring an additional 500 shares in the last quarter. Crews Bank & Trust acquired a new stake in GSK in the fourth quarter worth approximately $26,000. ST Germain D J Co. Inc. boosted its stake in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 522 shares in the last quarter. Sunbelt Securities Inc. increased its position in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after purchasing an additional 302 shares during the period. Finally, Sierra Ocean LLC bought a new stake in shares of GSK in the 4th quarter worth $32,000. Institutional investors own 15.74% of the company's stock.

GSK Stock Down 4.2 %

NYSE:GSK traded down $1.43 during trading hours on Wednesday, reaching $32.71. The company's stock had a trading volume of 3,711,279 shares, compared to its average volume of 4,560,737. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The company has a market cap of $67.69 billion, a price-to-earnings ratio of 20.55, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. GSK plc has a one year low of $31.72 and a one year high of $45.93. The business's 50-day moving average is $37.58 and its 200-day moving average is $36.40.

Remove Ads

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities research analysts predict that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a $0.3932 dividend. The ex-dividend date is Friday, February 21st. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.81%. GSK's dividend payout ratio is 98.74%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on GSK shares. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.